Format
Sort by

Send to

Choose Destination

Search results

Items: 16

1.

Donor registries, first-person consent legislation, and the supply of deceased organ donors.

Callison K, Levin A.

J Health Econ. 2016 Sep;49:70-5. doi: 10.1016/j.jhealeco.2016.06.009.

PMID:
27388535
2.

Medicare Managed Care Spillovers and Treatment Intensity.

Callison K.

Health Econ. 2016 Jul;25(7):873-87. doi: 10.1002/hec.3191.

PMID:
25960418
3.

Youth employment and substance use.

Kaestner R, Sasso AL, Callison K, Yarnoff B.

Soc Sci Res. 2013 Jan;42(1):169-85. doi: 10.1016/j.ssresearch.2012.07.007.

PMID:
23146605
4.

Variation of seizure frequency with ovulatory status of menstrual cycles.

Herzog AG, Fowler KM, Sperling MR, Liporace JD, Kalayjian LA, Heck CN, Krauss GL, Dworetzky BA, Pennell PB; Progesterone Trial Study Group..

Epilepsia. 2011 Oct;52(10):1843-8. doi: 10.1111/j.1528-1167.2011.03194.x.

5.

Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study.

Evon DM, Ramcharran D, Belle SH, Terrault NA, Fontana RJ, Fried MW; Virahep-C Study Group..

Am J Gastroenterol. 2009 Dec;104(12):2949-58. doi: 10.1038/ajg.2009.528.

PMID:
19789525
6.

Host genetics, steatosis and insulin resistance among African Americans and Caucasian Americans with hepatitis C virus genotype-1 infection.

Iuliano AD, Feingold E, Wahed AS, Kleiner DE, Belle SH, Conjeevaram HS, Zmuda J, Liang TJ, Yee LJ; Virahep-C Study..

Intervirology. 2009;52(1):49-56. doi: 10.1159/000214380.

7.

Interleukin-6 haplotypes and the response to therapy of chronic hepatitis C virus infection.

Yee LJ, Im K, Borg B, Yang H, Liang TJ; Virahep-C Study..

Genes Immun. 2009 Jun;10(4):365-72. doi: 10.1038/gene.2009.26.

8.

Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection.

Hoofnagle JH, Wahed AS, Brown RS Jr, Howell CD, Belle SH; Virahep-C Study Group..

J Infect Dis. 2009 Apr 15;199(8):1112-20. doi: 10.1086/597384.

9.

Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C.

Terrault NA, Im K, Boylan R, Bacchetti P, Kleiner DE, Fontana RJ, Hoofnagle JH, Belle SH; VIRAHEP-C Study Group..

Clin Gastroenterol Hepatol. 2008 Dec;6(12):1403-11. doi: 10.1016/j.cgh.2008.08.006.

10.

Polymorphism in the human major histocompatibility complex and early viral decline during treatment of chronic hepatitis C.

Yee LJ, Im K, Wahed AS, Bugawan T, Li J, Rhodes SL, Erlich H, Rosen HR, Liang TJ, Yang H; Virahep-C Study..

Antimicrob Agents Chemother. 2009 Feb;53(2):615-21. doi: 10.1128/AAC.00947-08.

11.

Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy.

Burton JR Jr, Klarquist J, Im K, Smyk-Pearson S, Golden-Mason L, Castelblanco N, Terrault N, Rosen HR; Virahep-C Study Group..

J Hepatol. 2008 Sep;49(3):329-38. doi: 10.1016/j.jhep.2008.05.020.

PMID:
18644644
12.

Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C.

Su X, Yee LJ, Im K, Rhodes SL, Tang Y, Tong X, Howell C, Ramcharran D, Rosen HR, Taylor MW, Liang TJ, Yang H; Virahep-C Study Group..

J Hepatol. 2008 Aug;49(2):184-91. doi: 10.1016/j.jhep.2008.04.011.

13.

Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment.

Carroll PV, Umpleby M, Alexander EL, Egel VA, Callison KV, Sönksen PH, Russell-Jones DL.

Clin Endocrinol (Oxf). 1998 Dec;49(6):739-46.

PMID:
10209561
14.

Systemic administration of rhIGF-I enhanced regeneration after sciatic nerve crush in mice.

Contreras PC, Steffler C, Yu E, Callison K, Stong D, Vaught JL.

J Pharmacol Exp Ther. 1995 Sep;274(3):1443-9.

PMID:
7562520
15.

The potential of insulin-like growth factor-I as a therapeutic for the treatment of neuromuscular disorders.

Lewis ME, Vaught JL, Neff NT, Grebow PE, Callison KV, Yu E, Contreras PC, Baldino F Jr.

Ann N Y Acad Sci. 1993 Aug 27;692:201-8. Review. No abstract available.

PMID:
8215023
16.

Selective down-regulation of D1 dopamine mediated rotational behavior in supersensitive mice.

Winkler JD, Callison K, Cass SA, Weiss B.

Neuropharmacology. 1988 Apr;27(4):439-42.

PMID:
3138558
Items per page

Supplemental Content

Loading ...
Support Center